UFSP2 (Gene)

Organism:

Homo sapiens

Synonyms:BHD, C4orf20, ENTREZ:55325, HGNC:25640, MIM:611482, NM_018359, NP_060829, NR_028085, NR_144317, SEMDDR, UFM1 specific peptidase 2, UFSP2

Omim:OMIM:611482

Id:ENSG00000109775

Hgnc:HGNC:25640

Entrez:55325

Ensembl:ENSG00000109775

Description:UFM1 specific peptidase 2

This gene encodes a highly conserved cysteine protease. The protein cleaves two C-terminal residues from ubiquitin-fold modifier 1, a ubiquitin-like post-translational modifier protein. Activation of ubiquitin-fold modifier 1 by the encoded protein exposes a C-terminal glycine residue that allows interaction with other proteins and transfer to its target protein. An allelic variant of this gene has been associated with Beukes hip dysplasia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2016]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View UFSP2's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with UFSP2.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using UFSP2.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for UFSP2.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with UFSP2.

Results found

Linked to

	Label	Description
	GSE226249 pirfenidone HL 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE208634 1 V 2 DOXYCYCLINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE120370 0 V 6 THROMBIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE77108 saha 0 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 2 V 7 PIRFENIDONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE181517 0 V 1 DOXORUBICIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE184210 0 V 1 GLUCAGON MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE77108 0 V 9 SAHA HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE125014 enzalutamide prostate gland 1 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE208350 H-7 Huh-7 JHH-7 0 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS

GSE226249 pirfenidone HL 2 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE208634 1 V 2 DOXYCYCLINE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE120370 0 V 6 THROMBIN MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE77108 saha 0 v 9 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE226249 2 V 7 PIRFENIDONE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE181517 0 V 1 DOXORUBICIN HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE184210 0 V 1 GLUCAGON MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE77108 0 V 9 SAHA HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE125014 enzalutamide prostate gland 1 v 5 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE208350 H-7 Huh-7 JHH-7 0 v 3 human up

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.